Investigational drug · Phase 3
CAM2029
Also called: octreotide depot
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Polycystic Liver Disease, Gastro-enteropancreatic Neuroendocrine Tumor, Acromegaly.
Phase 3Last checked: Nov 19, 2026Latest source record: Jul 28, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
2 still active
All registered trials
5
Any phase or sponsor naming "CAM2029"
First trial start
2019
Oct 10, 2019
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "CAM2029", any sponsor or status.
Conditions studied
As listed on its trial records.
- Polycystic Liver Disease
- Gastro-enteropancreatic Neuroendocrine Tumor
- Acromegaly
Approved drugs for the same conditions: Pancreatic cancer · Acromegaly · Oncology · Gastroenterology and liver · Endocrinology and women's health
Largest trials
Live from ClinicalTrials.gov: studies naming "CAM2029" as an intervention, largest first.
- A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NETPivotal-lookingActive, not recruiting
Camurus ABIndustry
NCT05050942 · 332 participants · Start Oct 22, 2021 · Primary completion Nov 2026
Drug: CAM2029; Octreotide LAR and 1 more · For: Gastro-enteropancreatic Neuroendocrine Tumor
Sites: Phoenix, Arizona; Santa Monica, California; Denver, Colorado · 86 sites in all
- A Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot in Patients With AcromegalyPivotal-lookingCompleted
Camurus ABIndustry
NCT04125836 · 135 participants · Start Oct 10, 2019 · Primary completion Apr 24, 2025
Drug: CAM2029 (octreotide subcutaneous depot) · For: Acromegaly
Sites: Los Angeles, California; Palo Alto, California; Miami, Florida · 68 sites in all
- A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With AcromegalyPivotal-lookingCompleted
Camurus ABIndustry
NCT04076462 · 72 participants · Start Aug 19, 2019 · Primary completion May 2, 2023
Drug: CAM2029 (octreotide subcutaneous depot); Matching placebo · For: Acromegaly
Sites: Los Angeles, California; Palo Alto, California; Miami, Florida · 63 sites in all
- A Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With PLDPivotal-lookingActive, not recruiting
Camurus ABIndustry
NCT05281328 · 71 participants · Start Jun 28, 2022 · Primary completion Feb 5, 2025
Drug: CAM2029; Placebo · For: Polycystic Liver Disease
Sites: Rochester, Minnesota; New York, New York; Philadelphia, Pennsylvania · 11 sites in all
Camurus ABIndustry
NCT02299089 · 12 participants · Start Jan 2015 · Primary completion May 2016
Drug: octreotide FluidCrystal® injection depot · For: Acromegaly; Neuroendocrine Tumors
Sites: Bron, France; Rouen, France; Bad Berka, Germany · 10 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- New and emerging pharmacological treatment options for acromegaly: a 2026 update.
Wildemberg LE, Marques NV, Kasuki L, et al. · Expert Opin Pharmacother 2026
- What is the future of acromegaly therapy?
Schilbach K, Strasburger CJ · J Clin Endocrinol Metab 2026
- Population Pharmacokinetic Analysis of an Octreotide Depot (CAM2029) in the Treatment of Acromegaly.
Glatard A, Friberg-Hietala S, Keutzer L, et al. · Clin Pharmacokinet 2025
- Octreotide Subcutaneous Depot for Acromegaly: A Randomized, Double-blind, Placebo-controlled Phase 3 Trial, ACROINNOVA 1.
Ferone D, Freda P, Katznelson L, et al. · J Clin Endocrinol Metab 2025
- "Cold" Somatostatin Analogs in Neuroendocrine Neoplasms: Decoding Mechanisms, Overcoming Resistance, and Shaping the Future of Therapy.
Massironi S, Albertelli M, Hasballa I, et al. · Cells 2025
- The current status of somatostatin analogs in the treatment of neuroendocrine tumors and future perspectives.
Lauricella E, Vilisova S, Chaoul N, et al. · Expert Rev Neurother 2025
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.